Abstract
Leber congenital amaurosis (LCA) is the earliest and most severe retinal degeneration (RD), and the most common cause of incurable blindness diagnosed in children. It is occasionally the presenting symptom of multisystemic ciliopathies which diagnosis will require a specific care of patients. Nineteen LCA genes are currently identified and three of them account for both non-syndromic and syndromic forms of the disease. RD3 (LCA12) was implicated as a LCA gene based on the identification of homozygous truncating mutations in two LCA families despite the screening of large cohorts of patients. Here we provide a comprehensive survey of RD3 mutations and of their clinical expression through the screening of a cohort of 852 patients originating worldwide affected with LCA or early-onset and severe RD. We identified three RD3 mutations in seven unrelated consanguineous LCA families - i.e., a 2 bp deletion and two nonsense mutations - predicted to cause complete loss of function. Five families originating from the Southern Shores of the Mediterranean segregated a similar mutation (c.112C>T, p.R38*) suggesting that this change may have resulted from an ancient founder effect. Considering the low frequency of RD3 carriers, the recurrence risk for LCA in non-consanguineous unions is negligible for both heterozygote and homozygote RD3 individuals. The LCA12 phenotype in our patients is highly similar to those of patients with mutant photoreceptor-specific guanylate cyclase (GUCY2D/LCA1). This observation is consistent with the report of the role of RD3 in trafficking of GUCYs and gives further support to a common mechanism of photoreceptor degeneration in LCA12 and LCA1, i.e., inability to increase cytoplasmic cGMP concentration in outer segments and thus to recover the dark-state. Similar to LCA1, LCA12 patients have no extraocular symptoms despite complete inactivation of both RD3 alleles, supporting the view that extraocular investigations in LCA infants with RD3 mutations should be avoided.
Introduction
Leber congenital amaurosis (LCA) represents the most severe end of the spectrum of inherited retinal dystrophies, typically manifesting as profound visual impairment or total blindness from birth. While the genetic landscape of LCA is diverse, the RD3 gene (associated with the LCA12 subtype) has historically been one of the least understood. Prior to this international collaborative effort, RD3 mutations had been documented in only two families globally. This rarity has hindered a comprehensive understanding of the gene's prevalence, the spectrum of pathogenic mutations, and the resulting clinical phenotype.
This study aimed to address these gaps through a large-scale, worldwide screening of 852 patients. By delineating the genetic and clinical characteristics of LCA12, the researchers sought to improve diagnostic accuracy, provide better genetic counseling, and establish a baseline for future therapeutic interventions.
Methods
The study employed a multi-center approach, pooling resources from ten research institutions across Europe, North America, and China. The primary cohort consisted of 852 unrelated patients: 574 with LCA, 96 with early-onset severe retinal dystrophy (EOSRD), and 182 with other forms of retinal degeneration such as retinitis pigmentosa.
Genetic screening involved direct sequencing of the two coding exons of RD3. Variants were assessed for pathogenicity using bioinformatics tools including SIFT and PolyPhen-2. For families exhibiting the same mutation, haplotype analysis using microsatellite markers was performed to investigate potential founder effects. Clinical evaluation of mutation-positive patients included comprehensive ophthalmological examinations, fundus photography, and Optical Coherence Tomography (OCT) to assess retinal architecture.
Results and Discussion
Genetic Findings and the Founder Effect
The screening identified three novel, homozygous truncating mutations in seven unrelated consanguineous families. These included two nonsense mutations (c.112C>T, p.R38 and c.319C>T, p.R107) and one 2-bp deletion (c.496_497del, p.G166fs*). These mutations are predicted to result in a complete loss of RD3 protein function.
A significant finding was the identification of the p.R38 mutation in five families originating from the Southern Mediterranean. Haplotype analysis (Figure 3) revealed a shared genetic signature among these families, suggesting the mutation arose from a common ancestor approximately 100–150 generations ago. Overall, RD3* mutations were found in approximately 1.2% of the LCA cohort, confirming its status as a rare but important genetic cause.
Clinical Phenotype and Biological Mechanism
The clinical phenotype of LCA12 was found to be remarkably consistent and strikingly similar to that of LCA1, caused by mutations in GUCY2D. Patients typically presented with extremely low visual acuity (light perception or hand movement) and a characteristic "salt and pepper" fundus appearance. OCT imaging revealed profound loss of the photoreceptor layer, while inner retinal layers were relatively preserved.
This clinical "mirroring" provides strong evidence for the biological role of RD3 as a chaperone protein. RD3 is essential for the trafficking of the guanylate cyclase enzyme (GUCY2D) to the photoreceptor outer segments. In the absence of functional RD3, GUCY2D fails to reach its destination, preventing the synthesis of cGMP necessary for the cell to recover its dark-state after light stimulation. This shared pathway explains the identical clinical presentations of LCA1 and LCA12.
Furthermore, the study confirmed that LCA12 is a non-syndromic condition. Despite the complete inactivation of RD3, patients showed no extraocular symptoms. This finding is clinically significant as it suggests that extensive systemic medical workups may be unnecessary once an RD3 mutation is confirmed.
Conclusion and Future Directions
This collaborative study provides the most comprehensive survey of RD3 mutations to date. By defining the genetic spectrum and clinical phenotype of LCA12, it paves the way for improved molecular diagnosis and genetic counseling. The clear link between RD3 and GUCY2D trafficking underscores the potential for gene replacement therapies. Given the existence of successful animal models, LCA12 is a prime candidate for future clinical trials aimed at restoring vision in affected children.
Summary updated